Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Jillian L. Scavone, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 560
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion StudyRyan J. Sullivan, Bob T. Li, Mario E. Lacouture et al.|Cancer Discovery|2017Cited by 418
Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasmsBenjamin H. Durham, Omar Abdel‐Wahab, Estibaliz Lopez Rodrigo et al.|Nature Medicine|2019Cited by 228
Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsRoger von Moos, Axel Hauschild, Beat Thuerlimann et al.|European Journal of Cancer|2008Cited by 128
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of LiteratureKarmela K Chan, Anne R. Bass, Cynthia M. Magro et al.|The Oncologist|2019Cited by 69